|
IL112969A
(en)
*
|
1994-03-17 |
2001-05-20 |
Baxter Int |
Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
|
|
AU5930396A
(en)
*
|
1995-05-25 |
1996-12-11 |
Baxter International Inc. |
Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
|
|
US5800539A
(en)
*
|
1995-11-08 |
1998-09-01 |
Emory University |
Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
|
|
US6805861B2
(en)
*
|
1996-01-17 |
2004-10-19 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic T lymphocytes (CTL)
|
|
US6213127B1
(en)
|
1996-07-29 |
2001-04-10 |
Emory University |
Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
|
|
US5834487A
(en)
*
|
1996-09-24 |
1998-11-10 |
Cv Therapeutics |
Inhibition of 26S and 20S proteasome by indanones
|
|
EP1011694A4
(en)
*
|
1996-11-15 |
2000-11-15 |
Baxter Int |
TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
|
|
US6428782B1
(en)
*
|
1997-05-23 |
2002-08-06 |
Hadasit Medical Research Services And Development Ltd. |
Non-myeloablative tolerogenic treatment
|
|
EP1037643B1
(en)
*
|
1997-10-10 |
2003-12-03 |
Meyer Pharmaceuticals, LLC |
Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
|
|
US20040033230A1
(en)
*
|
1997-12-24 |
2004-02-19 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
US6969518B2
(en)
*
|
1998-12-28 |
2005-11-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
US7598226B2
(en)
|
1998-12-28 |
2009-10-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
WO2001040269A2
(en)
*
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
JP4917201B2
(ja)
*
|
2000-12-04 |
2012-04-18 |
株式会社リンフォテック |
臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
|
|
KR20020060643A
(ko)
*
|
2002-06-04 |
2002-07-18 |
김진경 |
타인의 면역시스템을 이용하는 암의 치료 방법
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
AU2003253684A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20050112122A1
(en)
*
|
2003-09-02 |
2005-05-26 |
Greiner Dale L. |
Generation of hematopoietic chimerism and induction of central tolerance
|
|
WO2005079755A2
(en)
*
|
2004-02-12 |
2005-09-01 |
Nektar Therapeutics |
Interleukin-13 antagonist powders, spray-dried particles, and methods
|
|
EP1755685A4
(en)
*
|
2004-05-28 |
2008-11-12 |
Mayo Foundation |
METHODS FOR TRANSPLANTATION OF AUTOLOGOUS STEM CELLS
|
|
US9155789B2
(en)
*
|
2005-04-25 |
2015-10-13 |
New York University |
Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
|
|
JP5638804B2
(ja)
|
2006-08-04 |
2014-12-10 |
アストラゼネカ アクチボラグ |
ＥｒｂＢ２に対する抗体
|
|
EP2942057A1
(en)
|
2006-08-07 |
2015-11-11 |
AbbVie Biotherapeutics Inc. |
Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
|
|
US7842293B2
(en)
|
2006-08-07 |
2010-11-30 |
Facet Biotech Corporation |
Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
|
|
EP2089042A2
(en)
*
|
2006-11-08 |
2009-08-19 |
Aldagen, Inc. |
Methods for improved engraftment following stem cell transplantation
|
|
WO2008067126A2
(en)
*
|
2006-11-08 |
2008-06-05 |
Aldagen, Inc. |
Methods for using aldhbr cells to supplement stem cell transplantation
|
|
WO2011021503A1
(ja)
*
|
2009-08-17 |
2011-02-24 |
国立大学法人東京大学 |
一過性生着ｃｔｌを含む医薬品組成物
|
|
DK2793914T3
(da)
|
2011-12-22 |
2021-04-26 |
Yeda Res & Dev |
Kombinationsterapi til en stabil og langvarig transplantation
|
|
WO2016054354A1
(en)
|
2014-10-02 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating malignancies
|
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
|
EP4417210A1
(en)
|
2017-03-15 |
2024-08-21 |
Orca Biosystems, Inc. |
Compositions and methods for hematopoietic stem cell transplants
|